LIFECORE BIOMEDICAL, INC. Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit
LIFECORE BIOMEDICAL, INC. (LFCR) had Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit of $12.14 per share as of 2024-05-19, per its 10-K filed 2024-08-26.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit · last filed 2024-08-26
- LIFECORE BIOMEDICAL, INC. share-based payment arrangement, option, exercise price range, upper range limit for fiscal 2018 was $14.39.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit | Share-based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit 12 month |
|---|---|---|
| 2024-05-19 | $12.14 10-K · filed 2024-08-26 | |
| 2018-05-27 | $14.39 10-K · filed 2018-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |